Evidence map›Paper›PMID 41625335›Full record

ArticleFrontiers in pharmacology2025

Serine synthesis and transport mediate the synergistic and detoxifying effects of lienal peptides on cisplatin.

Ke Ding, Tengjie Yu, Xiaowei Zhang, Kangrui Hu, Shuying Mao, Tingting Zhang, Ye Liu, Zhongbo Wang, Xin Fan, Wei Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ke Ding *Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Tengjie Yu *Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Xiaowei Zhang *Nutrition Department, Hebei General Hospital, Shijiazhuang, Hebei, China.
Kangrui HuJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Shuying MaoJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Tingting ZhangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Ye LiuJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Zhongbo WangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Xin FanJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Wei LiuHebei Zhitong Biopharmaceutical Co., Ltd., Gucheng, Hebei, China.
Dianzhui ZhangHebei Zhitong Biopharmaceutical Co., Ltd., Gucheng, Hebei, China.
Laipeng HeHebei Zhitong Biopharmaceutical Co., Ltd., Gucheng, Hebei, China.
Lin XieJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Guangji WangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Yan LiangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lienal peptides (LPs), one kind of animal-derived traditional Chinese medicine, are used clinically as an adjunctive therapeutic drug in oncology. Cisplatin (DDP) is a broad-spectrum chemotherapy drug widely used for non-small cell lung cancer (NSCLC) but is limited by a series of toxic side effects. To date, the feasibility of using LPs and DDP in combination remains unclear. The present study aimed to explore the feasibility of LPs combined with DDP as an adjuvant therapy for NSCLC by examining the effects of LPs on the efficacy and toxicity of DDP. Our findings demonstrated that LPs exhibited significant antitumor activity in Lewis lung carcinoma (LLC)-bearing mice when administered either alone or combined with DDP. Moreover, LPs treatment notably improved survival rate, alleviated renal and hepatic impairment, and reversed DDP-induced metabolic disorder. Additionally, our data indicated that tumor growth led to dysregulated serine metabolism. LPs could significantly normalize serine levels by modulaitng the synthesis of serine in gut microbiota and its SFXN1-mediated transport in tumor cells. Thus, this study for the first time reveals the auxiliary anti-tumor effect of LPs from the perspective of amino acid metabolism, supporting LPs as a promising adjuvant to DDP in NSCLC.

Indexed as

cisplatinlienal peptidesmetabolomeserineSFXN1

Identifiers

PMID41625335
PMCPMC12855131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.